Iohexol is a leading contrast agent, indispensable for a variety of diagnostic imaging procedures. Its efficacy in enhancing visualization of internal body structures is well-established, but safe and effective use hinges on precise administration and a thorough understanding of its properties. This guide aims to provide healthcare professionals with key information regarding Iohexol dosage, administration techniques, and crucial safety precautions.

The dosage of Iohexol is highly dependent on the specific imaging procedure, the patient's age, weight, renal function, and the desired level of contrast enhancement. For instance, dosages for CT angiography of the head and neck will differ significantly from those used in excretory urography. Healthcare providers must consult specific protocols and product guidelines to determine the appropriate volume and concentration. Understanding the Iohexol properties and uses is fundamental to selecting the correct dosage regimen. For example, in examinations where enhanced visualization of renal structures is needed, higher concentrations might be employed.

Administration routes for Iohexol are diverse, reflecting its broad applicability. It is commonly administered intravenously for systemic imaging, such as CT scans of the torso or angiography. It can also be administered intra-arterially for specific vascular studies or introduced into body cavities, like the joints for arthrography. The speed of injection is also critical; rapid administration is often required to achieve optimal contrast opacification of blood vessels or organs. Thoroughly reviewing the Iohexol medical imaging applications and their associated administration protocols is essential for practitioners.

Safety precautions are paramount when administering Iohexol. A comprehensive patient assessment, including a history of allergies, particularly to iodine or contrast media, is a critical first step. The Iohexol side effect profile, while generally favorable, includes potential allergic reactions, ranging from mild skin rashes to severe anaphylaxis. Facilities should be prepared for managing such emergencies. Furthermore, the Iohexol excretion and kidney function must be carefully considered. Patients with pre-existing renal impairment may require dose adjustments or alternative imaging strategies. It is also vital to be aware of potential Iohexol drug interactions, especially with medications like metformin, which may need to be temporarily discontinued around the time of contrast administration to prevent nephropathy.

The CAS number 66108-95-0 ensures the correct identification of Iohexol. Sourcing this pharmaceutical-grade contrast agent from reliable suppliers is non-negotiable. Companies specializing in fine chemicals and pharmaceutical intermediates are key partners in ensuring product quality and availability. When purchasing Iohexol, verifying batch certifications and adherence to pharmacopeial standards is crucial. By adhering to these guidelines for dosage, administration, and safety, healthcare professionals can confidently utilize Iohexol to achieve accurate and informative diagnostic images, thereby improving patient care and outcomes.